Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects

Objectives: Somatostatin is an endocrine peptide hormone that regulates neurotransmission and cell proliferation by interacting with G protein-coupled somatostatin receptors (SSTRs). SSTRs are specific molecular targets of several radiotracers for neuroendocrine tumor (NET) imaging. Gallium-68 (68Ga)-DOTA-TATE is widely used for positron emission tomography/computed tomography (PET/CT) imaging of SSTRs and has shown a higher affinity for SSTR2, the most common SSTR subtype found in NETs. We aimed to analyze the distribution pattern of 68Ga-DOTA-TATE in normal subjects.Methods: A total of 617 consecutive 68Ga-DOTA-TATE PET/CT whole-body scans performed in our department from May 2015 through April 2020 with known or suspected neuroendocrine malignancies, mostly to evaluate adrenal adenomas, were retrospectively analyzed by 2 nuclear medicine physicians. One hundred eighteen subjects without a diagnosis of NET, with no tracer avid lesion of NET on 68Ga-DOTA-TATE PET/CT, and followed up for at least 6 months (average 2-3 years) without any biochemical, clinical, or imaging findings suggestive of NET were included in this study.Results: The highest uptake of 68Ga-DOTA-TATE was noted in the spleen followed by the kidneys, adrenal glands, liver, stomach, small intestine, prostate gland, pancreas head, pancreas body, thyroid gland, and uterus, in descending order. Minimal to mild uptake was detected in the submandibular glands, parotid glands, thymus, muscles, bones, breast, lungs, and mediastinum.Conclusion: Our study shows the biodistribution pattern of 68Ga-DOTA-TATE in normal subjects and the ranges of the maximum standard uptake value (SUVmax) and SUVmean values of 68Ga-DOTA-TATE obtained in several tissues for reliably identifying malignancy in 68Ga-DOTA-TATE PET/CT studies.

Anahtar Kelime:

Normal Olgularda 68Ga-DOTA-TATE’nin Fizyolojik Biyolojik Dağılımı

Öz:

Amaç: Somatostatin, G proteinine bağlı somatostatin reseptörleri (SSTR) ile etkileşerek endokrin sistemi, nörotransmisyonu ve hücre proliferasyonunu düzenleyen bir peptid hormonudur. SSTR’ler, nöroendokrin tümör (NET) görüntüleme için çeşitli radyoaktif madde işaretli spesifik moleküllerin hedefidir. Galyum-68 (68Ga)-DOTA-TATE, SSTR’lerin pozitron emisyon tomografisi/bilgisayarlı tomografi (PET/BT) görüntülemesinde yaygın olarak kullanılmaktadır ve NET’lerde bulunan en yaygın SSTR alt tipi olan SSTR2 için daha yüksek afinite gösterir.Yöntem: Mayıs 2015’ten Nisan 2020’ye kadar, çoğu adrenal adenomların değerlendirilmesi amacı ile olmak üzere, nöroendokrin malignitesi şüphesi olan veya NET tanılı olgulara bölümümüzde yapılan 617 68Ga-DOTA-TATE PET/BT tüm vücut taraması, iki nükleer tıp hekimi tarafından geriye dönük olarak incelendi. NET tanısı olmayan, 68Ga-DOTA-TATE PET/BT’de aktivite tutulumu gösteren lezyon saptanmayan ve klinik, biyokimyasal veya görüntülemede NET bulgusu olmaksızın en az 6 ay (ortalama 2-3 yıl) izlenen yüz on sekiz olgu bu çalışmaya dahil edilmiştir.Bulgular: En yüksek 68Ga-DOTA-TATE tutulumu dalakta kaydedildi ve bunu sırasıyla böbrekler, adrenal bezler, karaciğer, mide, ince bağırsak, prostat bezi, pankreas başı, pankreas gövdesi, tiroid bezi ve uterus takip etti. Submandibular bezlerde, parotis bezlerinde, timusta, kaslarda, kemiklerde, memede, akciğerlerde ve mediastende minimal veya hafif tutulum tespit edildi.Sonuç: Bu çalışma, 68Ga-DOTA-TATE PET/BT görüntülemede maligniteyi güvenilir bir şekilde tanımlayabilmek için normal olgularda 68Ga-DOTATATE’nin biyolojik dağılım modelini ve çeşitli organlardan elde edilen maksimum standardize uptake değeri (SUVmaks) ve SUVortalama değerlerinin aralıklarını gösterir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Bhanat E, Koch CA, Parmar R, Garla V, Vijayakumar V. Somatostatin receptor expression in non-classical locations - clinical relevance? Rev Endocr Metab Disord 2018;19:123-132.
2. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836-846.
3. Olsen JO, Pozderac RV, Hinkle G, Hill T, O’Dorisio TM, Schirmer WJ, Ellison EC, O’Dorisio MS. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med 1995;25:251-261.
4. van den Anker-Lugtenburg PJ, Krenning EP, Oei HY, Van Hagen MP, Gerrits CJ, Reubi JC, Lamberts SW, Löwenberg B. Somatostatin receptor scintigraphy in the initial staging of Hodgkin’s disease. Br J Haematol 1996;93:96-103.
5. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002;32:84-91.
6. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, Chiti A. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010;37:2004-2010.
7. Moradi F, Jamali M, Barkhodari A, Schneider B, Chin F, Quon A, Mittra ES, Iagaru A. Spectrum of 68Ga-DOTA TATE Uptake in Patients With Neuroendocrine Tumors. Clin Nucl Med 2016;41:281-287.
8. Ilhan H, Fendler WP, Cyran CC, Spitzweg C, Auernhammer CJ, Gildehaus FJ, Bartenstein P, Angele MK, Haug AR. Impact of (68) Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum. Ann Surg Oncol 2015;22:164-171.
9. Mojtahedi A, Thamake S, Tworowska I, Ranganathan D, Delpassand ES. The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. Am J Nucl Med Mol Imaging 2014;4:426-434.
10. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-518.
11. Al-Nahhas A, Win Z, Szyszko T, Singh A, Nanni C, Fanti S, Rubello D. Gallium-68 PET: a new frontier in receptor cancer imaging. Anticancer Res 2007; 27:4087-4094.
12. Kuyumcu S, Özkan ZG, Sanli Y, Yilmaz E, Mudun A, Adalet I, Unal S. Physiological and tumoral uptake of (68)Ga-DOTATATE: standardized uptake values and challenges in interpretation. Ann Nucl Med 2013;27:538-545.
13. Shastry M, Kayani I, Wild D, Caplin M, Visvikis D, Gacinovic S, Reubi JC, Bomanji JB. Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nucl Med Commun 2010;31:1025-1032.
14. Shimon I. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs. Endocrine 2003;20:265-269.
15. Sharma P, Mukherjee A, Bal C, Malhotra A, Kumar R. Somatostatin receptor-based PET/CT of intracranial tumors: a potential area of application for 68 Ga-DOTA peptides? AJR Am J Roentgenol 2013;201:1340-1347.
16. Anzola LK, Rivera JN, Dierckx RA, Lauri C, Valabrega S, Galli F, Moreno Lopez S, Glaudemans AWJM, Signore A. Value of Somatostatin Receptor Scintigraphy with 99mTc-HYNIC-TOC in Patients with Primary Sjögren Syndrome. J Clin Med 2019;8:763.
17. Druckenthaner M, Schwarzer C, Ensinger C, Gabriel M, Prommegger R, Riccabona G, Decristoforo C. Evidence for Somatostatin receptor 2 in thyroid tissue. Regul Pept 2007;138:32-39.
18. Albérini JL, Meunier B, Denzler B, Devillers A, Tass P, Dazord L, Le Simple T, Laissue J, de Jong R, Le Cloirec J, Reubi JC, Bourguet P. Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography. Breast Cancer Res Treat 2000;61:21-32.
19. Dude I, Zhang Z, Rousseau J, Hundal-Jabal N, Colpo N, Merkens H, Lin KS, Bénard F. Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography. EJNMMI Radiopharm Chem 2017;2:4.
20. Gugger M, Waser B, Kappeler A, Schonbrunn A, Reubi JC. Immunohistochemical localization of somatostatin receptor sst2A in human gut and lung tissue: possible implications for physiology and carcinogenesis. Ann N Y Acad Sci 2004;1014:132-136.
21. Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 2005; 92:1493-1498.
22. Melis M, Kaemmerer D, de Swart J, Kulkarni HR, Lupp A, Sänger J, Groen HC, Konijnenberg MW, de Jong M, Baum RP. Localization of Radiolabeled Somatostatin Analogs in the Spleen. Clin Nucl Med 2016;41:111-114.
23. Reubi JC, Horisberger U, Kappeler A, Laissue JA. Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs. Blood 1998;92:191-197.
24. Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, Brandau W, Mann K, Antoch G, Bockisch A, Petersenn S. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging 2011;38: 1224-1236.
25. Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage P, Pinzani M, Rosenbaum J, Geerts A. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 2004;1180-1189.
26. Reubi JC, Zimmermann A, Jonas S, Waser B, Neuhaus P, Läderach U, Wiedenmann B. Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999;45:766-774.
27. Brabander T, Teunissen J, Kwekkeboom D. Physiological Uptake in the Pancreatic Head on Somatostatin Receptor Scintigraphy Using [111In- DTPA]Octreotide: Incidence and Mechanism. Clin Nucl Med 2017;42:15-19.
28. Ionescu-Tirgoviste C, Gagniuc PA, Gubceac E, Mardare L, Popescu I, Dima S, Militaru M. A 3D map of the islet routes throughout the healthy human pancreas. Sci Rep 2015;5:14634.
29. Epelbaum J, Bertherat J, Prevost G, Kordon C, Meyerhof W, Wulfsen I, Richter D, Plouin PF. Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas. J Clin Endocrinol Metab 1995;80:1837-1844.
30. Gugger M, Waser B, Kappeler A, Schonbrunn A, Reubi JC. Cellular detection of sst2A receptors in human gastrointestinal tissue. Gut 2004;53:1431-1436.
31. Reubi JC, Horisberger U, Waser B, Gebbers JO, Laissue J. Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 1992;103:1207-1214.
32. Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 2015;35:500-516.
33. Balster DA, O’Dorisio MS, Summers MA, Turman MA. Segmental expression of somatostatin receptor subtypes sst(1) and sst(2) in tubules and glomeruli of human kidney. Am J Physiol Renal Physiol 2001;280:457-465.
34. Reubi JC, Horisberger U, Studer UE, Waser B, Laissue JA. Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. J Clin Endocrinol Metab 1993;77:1323-1328.
35. Reubi JC, Waser B, Schaer JC, Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 1995;80:2806-2814.
36. Green VL, Richmond I, Maguiness S, Robinson J, Helboe L, Adams IP, Drummond NS, Atkin SL. Somatostatin receptor 2 expression in the human endometrium through the menstrual cycle. Clin Endocrinol (Oxf) 2002;56:609-614.
37. Schulz S, Schmitt J, Weise W. Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer. Gynecol Oncol 2003; 89:385-390.

APA	Özgüven S, Filizoglu N, Kesim S, Öksüzoğlu K, SEN F, Ones T, Inanir S, TUROGLU H, erdil t (2021). Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects. , 39 - 46. 10.4274/mirt.galenos.2021.37268
Chicago	Özgüven Salih,Filizoglu Nuh,Kesim Selin,Öksüzoğlu Kevser,SEN FEYZA,Ones Tunc,Inanir Sabahat,TUROGLU Halil Turgut,erdil tanju yusuf Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects. (2021): 39 - 46. 10.4274/mirt.galenos.2021.37268
MLA	Özgüven Salih,Filizoglu Nuh,Kesim Selin,Öksüzoğlu Kevser,SEN FEYZA,Ones Tunc,Inanir Sabahat,TUROGLU Halil Turgut,erdil tanju yusuf Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects. , 2021, ss.39 - 46. 10.4274/mirt.galenos.2021.37268
AMA	Özgüven S,Filizoglu N,Kesim S,Öksüzoğlu K,SEN F,Ones T,Inanir S,TUROGLU H,erdil t Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects. . 2021; 39 - 46. 10.4274/mirt.galenos.2021.37268
Vancouver	Özgüven S,Filizoglu N,Kesim S,Öksüzoğlu K,SEN F,Ones T,Inanir S,TUROGLU H,erdil t Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects. . 2021; 39 - 46. 10.4274/mirt.galenos.2021.37268
IEEE	Özgüven S,Filizoglu N,Kesim S,Öksüzoğlu K,SEN F,Ones T,Inanir S,TUROGLU H,erdil t "Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects." , ss.39 - 46, 2021. 10.4274/mirt.galenos.2021.37268
ISNAD	Özgüven, Salih vd. "Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects". (2021), 39-46. https://doi.org/10.4274/mirt.galenos.2021.37268

APA	Özgüven S, Filizoglu N, Kesim S, Öksüzoğlu K, SEN F, Ones T, Inanir S, TUROGLU H, erdil t (2021). Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects. Molecular Imaging and Radionuclide Therapy, 30(1), 39 - 46. 10.4274/mirt.galenos.2021.37268
Chicago	Özgüven Salih,Filizoglu Nuh,Kesim Selin,Öksüzoğlu Kevser,SEN FEYZA,Ones Tunc,Inanir Sabahat,TUROGLU Halil Turgut,erdil tanju yusuf Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects. Molecular Imaging and Radionuclide Therapy 30, no.1 (2021): 39 - 46. 10.4274/mirt.galenos.2021.37268
MLA	Özgüven Salih,Filizoglu Nuh,Kesim Selin,Öksüzoğlu Kevser,SEN FEYZA,Ones Tunc,Inanir Sabahat,TUROGLU Halil Turgut,erdil tanju yusuf Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects. Molecular Imaging and Radionuclide Therapy, vol.30, no.1, 2021, ss.39 - 46. 10.4274/mirt.galenos.2021.37268
AMA	Özgüven S,Filizoglu N,Kesim S,Öksüzoğlu K,SEN F,Ones T,Inanir S,TUROGLU H,erdil t Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects. Molecular Imaging and Radionuclide Therapy. 2021; 30(1): 39 - 46. 10.4274/mirt.galenos.2021.37268
Vancouver	Özgüven S,Filizoglu N,Kesim S,Öksüzoğlu K,SEN F,Ones T,Inanir S,TUROGLU H,erdil t Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects. Molecular Imaging and Radionuclide Therapy. 2021; 30(1): 39 - 46. 10.4274/mirt.galenos.2021.37268
IEEE	Özgüven S,Filizoglu N,Kesim S,Öksüzoğlu K,SEN F,Ones T,Inanir S,TUROGLU H,erdil t "Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects." Molecular Imaging and Radionuclide Therapy, 30, ss.39 - 46, 2021. 10.4274/mirt.galenos.2021.37268
ISNAD	Özgüven, Salih vd. "Physiological Biodistribution of 68Ga-DOTA-TATE in Normal Subjects". Molecular Imaging and Radionuclide Therapy 30/1 (2021), 39-46. https://doi.org/10.4274/mirt.galenos.2021.37268